Clarity Pharmaceuticals宣布,公司的靶向铜诊疗产品以及相关临床开发项目将不会受到美国实施的100%关税政策影响。
该公司强调,尽管面临新的贸易政策挑战,其核心业务运营和产品开发计划仍将按既定方向推进,确保为患者提供创新的诊疗解决方案不会因外部贸易环境变化而受到干扰。
Clarity Pharmaceuticals宣布,公司的靶向铜诊疗产品以及相关临床开发项目将不会受到美国实施的100%关税政策影响。
该公司强调,尽管面临新的贸易政策挑战,其核心业务运营和产品开发计划仍将按既定方向推进,确保为患者提供创新的诊疗解决方案不会因外部贸易环境变化而受到干扰。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.